Analysts Are Bullish On Charles River Laboratories (CRL) Prospects

Core Insights - Charles River Laboratories International, Inc. (NYSE:CRL) is recognized as one of the top mid-cap AI stocks to invest in according to hedge funds, with a price target increase from $197 to $251 by TD Cowen, indicating a potential upside of 38.49% [1] - The firm anticipates solid quarterly results for Q4 and believes that the 2026 guidance could clarify operating conditions for investors [2] - A new gene therapy collaboration with Gazi University has been announced, focusing on advancing research for Hyperphosphatemic tumoral calcinosis (HTC) [3][4] Company Developments - The collaboration with Gazi University involves providing plasmid DNA for AAV production and support for in vitro efficacy studies, aimed at early-stage gene therapy programs [3][4] - Kerstin Dolph, Corporate Senior Vice President, emphasized the importance of this collaboration in transforming innovative concepts into real-world therapies [4] - Charles River Laboratories operates in various segments including Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions, and has a global presence [4]